Skip to main content

Table 2 Clinical characteristics of patients with Mycobacterium abscessus receiving intravenous amikacin therapy

From: Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series

Case

Age

Body Weight (Kg)

Dose of AMK (mg)/(mg/kg)

Duration of AMK therapy(months)

Prior Treatment

Regimen at Initiation of AMK

Sputum Conversion after AMK therapy

Sputum Conversion 1 year after AMK therapy

Radiological Findings after AMK therapy

#1

68

37

400/10.8

6

CAM,EB,RFP

CAM,EB,RFP,FAM

-

-

Unchanged

#2

54

49.

600/12.2

3

CAM,EB,RFP,LVFX

CAM,FAM,STFX

+

+

Improved

#3

59

56

700/12.5

4

CAM,EB,RFP

CAM,FAM,STFX

+

+

Improved

#4

66

48

400/15.0

4

CAM,EB,RFP

CAM,FAM,STFX

+

+

Improved

#5

61

46

400/8.3

4

CAM,EB,RFP,SM

CAM,EB,FAM,STFX

+

+

Improved

#6

86

49

600/12.2

8

CAM,IPM/CS

CAM,FAM,LVFX

+

-

Improved

#7

50

36

500/13.9

9

-

CAM,FAM,MINO

+

+

Worsened

#8

56

40

600/15.0

4

-

CAM,IPM/CS,MINO

+

+

Improved

#9

62

52

750/14.4

4

CAM,EB,RFP,LVFX,

CAM,IPM/CS,MINO

+

+

Worsened

#10

65

46

600/13.0

4

CAM,EB,RFP,SM,STFX,FAM

CAM,RFP,FAM

+

+

Worsened

#11

69

43

700/16.2

4

-

CAM,IPM/CS

-

-

Worsened

#12

67

35

400/11.4

9

CAM,EB,RFP,SM

CAM,RFP,FAM

-

-

Unchanged

#13

65

44

400/9.1

6

CAM,EB,RFP

CAM,FAM

+

-

Improved

  1. M male, F female, CAM clarithromycin, EB ethambutol, RFP rifampicin, LVFX levofloxacin, SM streptomycin, STFX sitafloxacin, FAM faropenem, IPM/CS imipenem/cilostazol, MINO minocycline